What matters most is rotating the physical body location where you inject, not the day or time
Many of the cardiovascular and metabolic trials informing the discussion were not designed to evaluate ophthalmic outcomes. The authors called for prospective ophthalmology-specific studies incorporating imaging biomarkers, visual outcomes and disease-specific monitoring, noting that parsing the protective benefits or adverse effects of this rapidly growing medication class will be essential to refining disease management and improve patient outcomes. As GLP-1 therapies become increasingly common among patients with diabetes, obesity and vascular comorbiditiesprecisely the populations populating ophthalmic clinicsthe field may not have the luxury of waiting for cleaner data
Its use outside of formally approved clinical trials is not sanctioned
J Ethnopharmacol 106, 353359, 10.1016/j.jep.2006.01.010 (2006)
If you want a deeper dive into the treatment landscape, our post on what GLP-1 support is and how it can transform your weight loss journey offers additional context
Cellular stress response (hormesis) in response to bioactive nutraceuticals with relevance to Alzheimer disease
